HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Branding For J&J’s Kenvue Cements Consumer Division Separation

Executive Summary

In advance of spinning off its consumer division in 2023, Johnson & Johnson has announced the new standalone company will be called Kenvue.

You may also be interested in...



Consumers Know Kenvue's Brands, But What About ‘Opportunity To Expand Usage Occasions’?

“That’s what makes this space very attractive, the ability to expand usage occasions to give consumers around the world new opportunities to take care of their health,” says CEO Thibaut Mongon. Some investors aren’t clear on what to expect from company operating entirely in consumer health since spinout from J&J.

J&J Limited On Offering Consumer Business Separation Details, Clear On Q4 Revenue Drag

“We made significant progress towards the separation of Kenvue,” says CEO Jaoquin Duoto. But fourth-quarter and full-year progress on consumer sales growth was impeded by loss to foreign currency exchange.

US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?

Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel